{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"20"},{"groupId":"OG003","value":"31"},{"groupId":"OG004","value":"2"}],"units":"Participants"}],"description":"Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.","groups":[{"description":"Males undergoing first transplant who did not receive leuprolide.","id":"OG000","title":"Males That Did Not Receive Leuprolide for 1st Transplant"},{"description":"Males undergoing first transplant who were randomized to receive leuprolide.","id":"OG001","title":"Males Randomized to Receive Leuprolide for 1st Transplant"},{"description":"Females undergoing first transplant who all received leuprolide.","id":"OG002","title":"Females That Received Leuprolide for 1st Transplant"},{"description":"Individuals related to patients and who gave hematopoietic stem cells for patients receiving allogeneic Bone Marrow Transplant on this study.","id":"OG003","title":"Matched Related Donors for Transplant"},{"description":"Patients receiving second allogeneic Bone Marrow Transplant on this study.","id":"OG004","title":"Recipients of 2nd Transplant"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"40/45 transplant recipients and all 31 donors were evaluable for adverse events as five patients did not proceed to transplant after enrollment due to progression of disease in four cases and enrollment on a new protocol in one case.","reportingStatus":"POSTED","timeFrame":"Date treatment consent signed to date off study, approximately 79 months and 11 days.","title":"Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)","type":"SECONDARY","unitOfMeasure":"Participants"}